Comparison of primary and secondary endpoints
| A. Hot flash frequencies | |||
|---|---|---|---|
| Number of daily hot flashes | p Value* | ||
| Hypnotherapy (n=7) | Gabapentin (n=8) | ||
| Median (range); n | Median (range); n | ||
| Baseline | 5.0 (2, 11); 7 | 4.5 (2, 9); 8 | 1.0 |
| Week 4 | 4.0 (1, 7); 6 | 4.0 (2, 9); 7 | 0.7 |
| Week 8 | 1.0 (0, 7); 6 | 3.0 (3, 5.5); 5 | 0.3 |
| Percentage of decrease† | 80% | 33.3% | |
| B. Hot flash severity scores (HFSSs) | |||
| HFSS | |||
| Hypnotherapy (n=7) | Gabapentin (n=8) | ||
| Median (range); n | Median (range); n | p Value* | |
| Baseline | 10.0 (2.0, 14.0); 7 | 7.5 (2.0, 19.0); 8 | 0.7 |
| Week 4 | 6.5 (1.0, 11.0); 6 | 4.0 (2.0, 17.5); 7 | 0.6 |
| Week 8 | 1.5 (0, 12.0); 6 | 5.0 (3.0, 11.5); 5 | 0.3 |
| Percentage of decrease | 85% | 33.3% | |
| C. Hot Flash Related Daily Interference Scale (HFRDIS) scores | |||
| HFRDIS | |||
| Hypnotherapy (n=11) | Gabapentin (n=14) | ||
| Median (range); n | Median (range); n | p Value* | |
| Baseline | 58.0 (16, 64); 11 | 45.5 (11, 82); 14 | 0.8 |
| Week 4 | 25.5 (1, 57); 6 | 12.5 (0, 57); 8 | 0.8 |
| Week 8 | 26.0 (0, 68); 9 | 22.0 (7, 41); 7 | 0.9 |
| Percentage of decrease | 55.2% | 51.6% | |
*Wilcoxon rank-sum test/Mann-Whitney U test.
†Percentage decrease over 8-week treatment period was calculated as (baseline median−week 8 median)/baseline median.